The question
Our client is developing a new approach for diagnosing Alzheimer’s disease. Today, there are different methods to identify the disease – mostly based on data that’s collected from blood and/or other fluids. This data identifies certain biomarkers which are indicators of Alzheimer’s. The trouble with these methods is that the data isn’t always enough – and needs back up tests such as psychological and functional tests.
Our client wants to better their understanding of the current ways of diagnosing, the diagnostic pathway and wants to expand the awareness and usage of a biomarker – which is based on cerebrospinal fluid (CSF): a body fluid which is found in the brain and spinal cord.
The question at hand: does this new method have potential for a successful launch in the current market?